Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04162756
Title Study of KTE-X19 for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18)
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Kite, A Gilead Company

mantle cell lymphoma


Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.